Post by Egle Therapeutics

We’re proud to share that #HorizonEurope, the European Commission's key funding program for research and innovation, has awarded Egle and our consortium partners approximately €8 million to advance the clinical development of EGL-001 in neoadjuvant head and neck cancer! This funding from the European Union will support an Egle-led initiative in partnership with a consortium of four leading European scientific institutions to accelerate the clinical development and translational research of EGL-001, a novel CTLA-4 x IL-2m fusion antibody that selectively depletes regulatory T cells (Tregs) within the tumor microenvironment. We’re grateful for this opportunity to bring novel Treg-based therapies like EGL-001 closer to patients in need and to work closely with our consortium partners at University College London (United Kingdom), Vall d’Hebron Institute of Oncology (VHIO) (Spain), Gustave Roussy (France), and Technical University of Dresden (Germany). To learn more, read our press release here: https://lnkd.in/eddY7usn